Alexios N. Matralis

TL;DR: Novel benzoxazine and benzothiazine derivatives that significantly inhibit in vitro microsomal lipid peroxidation and LDL oxidation as well as squalene synthase activity and show antidyslipidemic and antioxidant properties in vivo are presented.

TL;DR: The synthesis and evaluation of novel compounds in which antioxidant, anti-inflammatory, and squalene synthase (SQS) inhibitory/hypolipidemic activities are combined in simple molecules through design render them interesting lead compounds for further evaluation against atherosclerosis.

TL;DR: The up to date research and literature on the therapeutic potential of this relatively new class of compounds, the drug discovery efforts towards the development of active squalene synthase inhibitors, their activity profile and effectiveness, as well as their structure-activity relationships are reviewed.

TL;DR: This review describes the successful application of MTD for disorders such as neurodegenerative, cardiovascular, diabetes, metabolic and inflammatory diseases, especially focusing on the field of atherosclerosis where multi-target strategies are a promising alternative to the classical "one target-one drug" design approach.

TL;DR: The synthesis of 17 new morpholine derivatives which structurally vary in terms of the aromatic substitution on the morpholine ring are reported, which simultaneously suppress cholesterol biosynthesis through SQS inhibition and exhibit significant protection of hepatic microsomal membranes against lipid peroxidation.